Korro Bio Inc. (KRRO)
Korro Bio Inc. (KRRO) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 196.73M |
| Revenue (ttm) | 2.38M |
| Net Income (ttm) | -106.64M |
| Beta | 2.21 |
| EPS (ttm) | -9.88 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3 |
| P/B (ttm) | 1.90 |
| P/S (ttm) | 82.59 |
| Earnings Date | Nov 12, 2026 |
| Ask | n/a |
| Volume | 87,496 |
| Avg. Volume (20D) | 196,353 |
| Open | 13.39 |
| Previous Close | 13.35 |
| Day's Range | 12.89 - 13.93 |
| 52-Week Range | 5.20 - 55.89 |
| Analyst | Strong Buy |
| Price Target | 21.5 (60.93%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The ...
Financial Performance
In 2025, Korro Bio's revenue was 6.39M, an increase of 181.46% compared to the previous year's 2.27M. Earnings were -117.26M, an increase of 40.3%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for KRRO stock is "Strong Buy". The 12-month stock price forecast is 21.5, which is upside of 60.93% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
